We assessed the effectiveness of iron+folic acid for the treatment of severe anemia [hemoglobin (Hb) ,70 g/L] and the efficacy of added multivitamins and/or anthelminthics among children aged 6-24 mo in periurban Karachi, Pakistan. The study design was a double blind, placebo-controlled, randomized trial of currently recommended daily iron (25 mg) and folic acid (100 mg) for 90 d with daily multivitamins [vitamin A (300 mg, as retinol palmitate), vitamin E (6 mg tocopherol equivalents), vitamin B-12 (0.9 mg), vitamin C (15 mg), riboflavin (0.5 mg)] and/or anthelminthics (100 mg mebendazole twice daily for 3 d) compared with placebos. Treatment response was defined as reaching a Hb concentration $100 g/L at the end of 90 d. The prevalence of severe anemia in the 9518 children screened was 5.7% and a total of 462 severely anemic children were enrolled in the study. Adherence to treatment was~70% for iron+folic acid,~80% for multivitamins, and almost 100% for mebendazole. Children receiving iron+folic acid alone had a response rate of 38.7% at 90 d. The additional treatment with mebendazole or multivitamins did not significantly improve cure rates or change the Hb concentration over and above iron+folic acid treatment alone. Adherence to iron+folic acid of higher than the median resulted in a better treatment response rate of 50%. High-dose daily iron+folic acid performed as well as iron+folic acid with anthelminthics and multivitamins in the treatment of severe anemia in this setting. Higher adherence may be important in enhancing treatment impact. J. . 5 Abbreviations used: AGP, a-1 acid glycoprotein; CRP, C-reactive protein; DBS, dried blood spot; Hb, hemoglobin; LAZ, length for age Z-score; OR, odds ratio; TfR, transferrin receptor; WLZ, weight for length Z-score.
Introduction
A combination of high-iron needs and low-iron diets make childhood one of the highest risk periods for iron deficiency and anemia, particularly from 6-24 mo of age (1) . Severe anemia in early childhood, defined as hemoglobin (Hb) 5 concentration ,70 g/L, can result in increased morbidity and mortality (2) .
The major causes of anemia in young children in South Asia are largely preventable through public health measures. This age group is particularly vulnerable to iron deficiency due to increased requirements for rapid growth and an inadequate dietary intake of complementary foods containing bioavailable forms of iron (3) . Diets consumed in South Asia are predominantly cereal based and are low in animal products and high in foods that inhibit iron absorption. In addition to iron, deficiency of vitamins such as folic acid, vitamin A, vitamin C, riboflavin, and vitamin E can also inhibit erythropoiesis (4) and are also deficient in young children's diets (5, 6) . The current international recommendation for treatment of anemia (7) , however, does not include vitamins other than folic acid.
Apart from the nutritional causes, 2 major infectious causes of severe anemia are geohelminths and malaria. The health consequences of helminth infections in preschool children have not been extensively studied, because in young children, these are less prevalent and of lower intensity than in schoolchildren (8) . However, a recent trial among Zanzibar children aged 6-71 mo found that mebendazole treatment caused a significant reduction in anemia among very young children with low burden of hookworm, suggesting that incident infections may stimulate inflammatory immune responses with deleterious effects on erythropoiesis (9) . Also, Plasmodium falciparum infection contributes to the incidence and severity of anemia in regions of the world where it is endemic. Malaria likely causes anemia through a variety of mechanisms, including decreased iron absorption, altered iron metabolism (10) , suppression of erythropoiesis (11) , or decreased RBC life span. Controlled trials of malaria chemoprophylaxis have resulted in Hb improvements in infants (11) and children (12) .
The current international recommendations for treatment of severe anemia in young children include daily high-dose iron (25 mg) and folic acid (100 mg) therapy for 90 d (7) . However, the basis for these guidelines is not clear, nor has the effectiveness of the recommended dosage for treatment of severe anemia been previously evaluated. Second, the effect of multivitamins and anthelminthic treatment over and above iron+folic acid as the standard of care has not been tested. The aims of this study were to test the effectiveness of the current standard of care of iron+ folic acid for treating severe anemia among young children (6-24 mo of age) and to examine the efficacy of 2 enhanced treatment protocols in the treatment of severe anemia, namely, deworming using a 3-d treatment regimen and daily multivitamins for 90 d.
Materials and Methods

Study design and population
We tested the effectiveness of the standard of care (iron+folic acid) for treatment of severe anemia (Hb ,70 g/L) in young children by conducting a follow-up assessment at 90 d. Also, using a randomized, controlled, 2 3 2 factorial design, we tested 2 enhanced regimens viz. mebendazole and multivitamins. The 4 treatment groups were: iron +folic acid alone, iron+folic acid and mebendazole, iron+folic acid and multivitamins, and iron+folic acid and mebendazole and multivitamins. Both the mebendazole and multivitamin treatments included identical placebos. The standard of care of iron+folic acid was provided to everyone. We hypothesized that compared with the standard of care, mebendazole and/or daily multivitamins given for 90 d would result in a treatment response of $25%.
The study was conducted in 5 periurban communities in Karachi, Pakistan (Ibrahim Hyderi, Ali Akhbar Shah Goth, Rehri Goth, Bilal Colony, and Lalabad) between February 2005 and April 2007. The settlements were densely populated, had low rates of immunizations, high rates of undernutrition, and consisted of largely illiterate migrant workers, fishermen, laborers, and their families.
Treatments
Iron+folic acid. The iron+folic acid treatment consisted of a sweet, vanilla-flavored dispersible tablet each containing iron (ferrous sulfate,12.5 mg) and folic acid (50 mg) manufactured by Nutriset. The tablets were packaged in blister-packs of 14.
Multivitamins. Multivitamins were in the form of chewable chocolateflavored tablets containing vitamin A (300 mg retinol palmitate), vitamin E (6 mg a-tocopherol equivalents in the form of vitamin E succinate), vitamin B-12 (0.9 mg), ascorbic acid (15 mg), riboflavin (0.5 mg), or an identical placebo. Supplements were manufactured and bottled by Nutrilite Division of the Access Business Group.
Anthelminthics. Anthelminthic treatment consisted of mebendazole (100 mg twice per day for 3 d) as a white-colored, sweet suspension or an identical placebo suspension manufactured by GlaxoSmithKline and packaged in bottles.
Both the mebendazole and multivitamin bottles were labeled with unique treatment codes by the manufacturers and kept in a sealed envelope in Baltimore and Karachi.
At enrollment, parents were given 2 blister-packs of the iron+folic acid tablets, instructed on how to dissolve the tablet in water or breast milk, and asked to give 2 tablets/d to their child at night after meals for 90 d. Also, they were given a bottle containing 15 multivitamin or placebo tablets and asked to give 1 tablet/d to their child for 90 d. After the enrollment visit, study staff visited the home of each subject weekly to count and record the number of iron+folic acid and multivitamin/ placebo supplements that had been given to the child, resolve any adherence problems, and replenish the supplements. The first of the 6 doses of mebendazole or identical placebo syrup was administered during the enrollment clinic visit. Home visits were made by study staff on the 2 consecutive days to assess adherence to the deworming treatment. The iron+folic acid blister-packs were collected and the number of missing tablets out of the total given was counted. Similarly, the number of multivitamin tablets given each week and remaining in the bottle at the end was counted to calculate adherence.
Sample size
Our sample size estimate was based on being able to detect a $25% treatment response with the added treatments compared with the standard of care alone and assuming a response rate of 50% and a prevalence of 10% of severe anemia in the control group. This response rate is based on data showing that one-half of all anemia globally is attributable to iron deficiency. After accounting for a loss to follow-up of 20%, the sample size required was 300/group. We expected to screen 6000 children to achieve this sample size.
Screening and enrollment
All children between the ages of 6 and 24 mo in the study area were identified and enumerated by female workers. Screening and enrollment of severely anemic young children took place over a period of slightly ,2 y (March 2005 to January 2007) during 3 surveillance rounds conducted every 10-12 mo. Children of consenting parents underwent a heel prick blood draw to assess Hb concentration using a HemoCue machine by 8 study phlebotomists. After the initial screening, severely anemic children were invited to a study clinic on the following day. The mothers of moderately and mildly anemic children received an iron syrup (iron polymaltose complex).
All workers conducting Hb measurements received rigorous training prior to beginning data collection. A protocol was developed to clean the HemoCue machine regularly as specified in the manual. Every day the FIGURE 1 Study participation and follow-up. 1 Not met (n = 563); refused (n = 1626); moved permanently (n = 711); died (n = 65). 2 Critical illness alone (n = 12); labored breathing alone (n = 5); critical illness and labored breathing (n = 8); edema alone (n = 1); edema and critical illness (n = 2); edema and labored breathing (n = 1).
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Enrollment clinic visit
At enrollment, severely anemic children received a clinical examination by the study medical officer. Children were excluded if they presented 1 of the following symptoms: labored breathing, edema, or a critical illness (including convulsions, inability to drink, vomiting, unconsciousness, or lethargy). These children were provided treatment at the clinic and/or referred to and assisted to reach and receive treatment at a hospital. Eligible children were enrolled in the study after obtaining written consent from at least 1 parent. Children were randomly allocated to 1 of the 4 treatment arms using a computer-generated randomization list containing 600 numbers, ranging from 1-4, and in randomly arranged blocks of 4.
Anthropometry (weight, height, and mid upper arm circumference) was conducted and blood was collected for malarial blood smears and dried blood spot (DBS) for retinol and protein analysis. Weight was measured to the nearest 0.1 kg using a digital scale. Length was measured in triplicate to the nearest 0.1 cm using a wooden length board (Shorr Products). The mothers of enrolled children were interviewed to assess household socioeconomic characteristics and their child's morbidity history and dietary intakes using a 7-d food frequency recall method.
At 7 and 28 d after initiation of treatment, Hb measurements were taken by the phlebotomists in the homes of the children to identify and refer nonresponders. After this, children were tested for Hb by the medical officer at a final clinic visit scheduled at~90 d. An endline interview, anthropometric measurements, and blood spot collection on filter paper were also conducted. Stool specimens were collected at the 28-d and final clinic visits.
Laboratory analyses
Malaria testing was conducted with routine microscopy using thick and thin blood smears fixed with ethanol and stained with Giemsa and read by light microscope with 1003 oil immersion lens. The number of malaria parasites (parasite density) was counted against leukocytes using the thick smear and identification of species was done using the thin smear. For those who were found to have malarial parasitemia, treatment was provided within 1 wk of receiving the laboratory results.
The method for examining stool samples was the Kato-Katz cellophane quantitative thick smear technique described by Ash et al. (13) . The Kato-Katz is an indirect measure of the intensity of infection and provides the number of eggs per gram of feces. Ascaris lumbricoides, Ancylostoma duodenale/Necator americanus (hookworm), and Trichuris trichiura eggs were counted and expressed as eggs per gram of fecal sample.
DBS retinol analysis was conducted at the micronutrient laboratory at the Aga Khan University using a modified reverse-phase HPLC (Perkin Elmer Series 200) after a simple extraction method described by Erhardt et al. (14) . Limited samples (85 at baseline and 69 at endline) of DBS were sent to Germany where they were analyzed for transferrin receptor (17) . Missing data were due to implausible Z-score values that were deleted. 3 Includes beef and goat. 4 Includes milk tea.
(TfR), C-reactive protein (CRP), and a-1 acid glycoprotein (AGP) using the sandwich ELISA developed by Erhardt (15) .
Statistical analysis
Treatment success or response was defined a priori as Hb $100 g/L at the 90-d follow-up visit. Nonresponders were children whose 7-and 28-d Hb concentrations had decreased by $3 g/L or had not improved by $3 g/L over their baseline Hb concentration, respectively. Baseline characteristics of the young children were compared across treatment groups using ANOVA for normally distributed continuous variables and a chisquare test for categorical variables. Percent adherence to treatment, nonresponse to treatment at 7 and 28 d, and impact of deworming treatment on geohelminth prevalence by treatment groups were also examined using a chi-square test. We assessed the overall and adherencestratified treatment effectiveness of the standard of care (i.e. iron+folic acid) alone and for all groups combined based on a post-treatment response rate at 90 d. We examined if the combined effects of the 2 enhanced interventions were greater than their additive effect. Because no synergistic interaction was found, we analyzed the 2 enhanced treatments separately using logistic regression analysis to test for main effects. As done in a 2 3 2 factorial design, groups that had mebendazole were compared with those that did not. Similarly, groups with and without multivitamin were compared. We further examined whether adherence to iron+folic acid treatment, age, baseline Hb concentration, and sex at enrollment modified the effect of the 2 enhanced interventions. Linear mixed effects regression analyses were conducted to examine the change in Hb concentration over the 90-d treatment regimen using all the longitudinal measured Hb assessments for each enhanced treatment (16) . All analyses were performed using Stata version 9.1 (StataCorp).
Ethical reviews and data safety and monitoring. The study was initially approved and annually rereviewed and approved by the Internal Review Boards at Johns Hopkins University Bloomberg School of Public Health and the Aga Khan University. A Data Safety and Monitoring Board was formed prior to the start of the study and met annually thereafter.
Results
Over the course of~2 y, 12,483 children aged 6-24 mo were enumerated during a census out of which 9518 were screened for severe anemia (Fig. 1) . The prevalence of severe anemia was 5.7% (n = 544). Of 515 eligible children, 462 (89.7%) were enrolled and completed the enrollment interview. Of the 462 children enrolled, 428 (92.6%), 404 (87.4%), and 378 (81.8%) were available for the 7-, 28-, and 90-d assessments, respectively. Attrition over the course of the 90-d treatment was due to: refusal to blood drawing, ranging from 3 to 10%; not meeting the child, ranging from 2 to 5%; permanent migrations outside study area, ranging from 0 to 5%; and 1 infant death. At baseline, characteristics of the enrolled children did not differ by treatment group ( Table 1) . The mean age of enrolled children was 16.1 mo, with more than one-half of them aged between 18 and 24 mo of age (data not shown). The mean DBS retinol concentration of~0.55 mmol/L was low across the treatment groups. Over one-half of the enrolled children were classified as stunted [,22 length for age Z-score (LAZ)] and one-fifth were classified as wasted [22 weight for length Z-score (WLZ)]. More males than females were enrolled in the study. The Hb distribution did not differ across the groups with~5, 10-15, and 80-84% of children having Hb concentrations ,50, 50-59, and 60-69 g/L, respectively. Approximately 50% of the children were still breast-feeding at enrollment. Less than 15% of the children had consumed heme iron (beef or goat meat) in the past week and one-third had consumed any citrus fruits, known enhancers of iron absorption. However, over 80% of children had consumed tea, a potent inhibitor of iron absorption. Malaria prevalence was low (2.2%), with 5 cases of P. falcipaurm, 3 cases of P. vivax, and 2 cases with both species. In a small sample (n = 85), protein analyses showed that TfR, CRP, and AGP concentrations did not differ across groups at baseline; the median (intraquartile range) for these proteins for all groups combined was 23.7 (11.2-36.1) mg/L, 1.5 (0.25-5.30) mg/L, and 1.2 (0.88-1.53) g/L, respectively (data not shown). The prevalences of high CRP (.5 mg/L) and AGP (.1 g/L) were high at baseline at 25.9 and 67.1%, respectively. The prevalence of high CRP was significantly higher in the multivitamin and that of high AGP was significantly higher in the mebendazole group than in their respective comparison groups. The median adherence of~70% for iron+folic acid was moderate and did not differ by treatment group ( Table 2) . The median adherence to treatment for mebendazole was high at .94%, whereas the median adherence to multivitamins was 80%.
The response to treatment using Hb . 100g/L for all groups combined was 42.6%, whereas that for the control group was 38.7%. Only~20% of children at the end of the treatment period were nonanemic (Hb . 110 g/L). Response rates were significantly higher at adherence levels above the median for iron+folic acid supplementation than those below the median; treatment response was 50.9 and 31.5%, respectively, for all groups combined and 51.1 and 26.1%, respectively, in the control group. Nonresponse to treatment at 7-and 28-d postenrollment was 4.3 and 10.3%, respectively, in the control group (data not shown). The nonresponse rates were lower in the groups receiving either or both additional treatments, but the differences between the treatments and the control did not differ.
Hookworm and Trichuris geohelminths were not prevalent in this population. Treatment with mebendazole reduced (P , 0.05) the prevalence of Ascaris at both the 28-d (9.5 vs. 3.2%) and 90-d (10.7 vs. 2.6%) assessments ( Table 3) .
Response to treatment did not differ between those receiving mebendazole and those who did not [odds ratio (OR) = 1.26; 95% CI: 0.84, 1.90] or between those receiving multivitamins and those who did not (OR = 1.01; 95% CI: 0.67-1.52) ( Table  4 ). Stratified analyses revealed no effect modification by adherence to daily iron+folic acid treatment or age, although the P-value for interactions between baseline Hb level and sex and the multivitamin treatment was ,0.05. The significant daily increment in Hb of~0.30 g/L did not differ between treatment groups ( Table 5) .
Mean DBS retinol concentrations increased from~0.56 mmol/L at baseline to~0.84 mmol/L at follow-up, whereas mean TfR concentrations decreased from~24 to~9 mg/L across all 4 groups (data not shown). The prevalence of high CRP (.5 mg/L) and AGP (.1 g/L) did not differ by treatment group at the follow-up assessment, although the prevalence of high AGP was lower at baseline at 46.4% for all groups combined (P , 0.05) but not for elevated CRP (27.5%).
Discussion
Our study demonstrated a~40% response rate to treatment using the current standard of care of daily high-dose iron+folic acid for 90 d among severely anemic children 6-24 mo of age in a periurban population of Karachi where the prevalence of severe anemia was high. The prevalence of malaria (,3%) and hookworm (0%) was low in this population, with only A. lumbricoides infection found in~6% of children. Our definition of response was established a priori and was conservative, but we found few children had achieved normal Hb concentrations of .110 g/L with the current recommended treatment guidelines for severe anemia (7) . Overall, adherence to treatment was lower at 70% than expected despite weekly visits by project workers to monitor tablet intake and replenishment. It is possible that the variability in adherence could explain in part the low response to treatment; higher adherence caused response rate to increase to 50%. Although we did not collect systematic data on reasons for nonadherence, mothers reported diarrhea and other illness as being a reason, as well as forgetting to give the tablets. Whereas iron deficiency is a leading cause of nutritional anemia, several hematinic nutrients, including vitamins A, E, B-12, C, and riboflavin, when deficient, can adversely affect irondependent erythropoiesis and contribute to anemia (4) . We found no evidence that adding these vitamins at an approximate U.S. Institute of Medicine-recommended daily allowance for children of this age to the standard iron+folic acid treatment improved response rates or increased Hb concentrations more. This was despite the poor nutritional quality of complementary foods fed to these children, as reflected in the low proportion of children being fed any heme iron or citrus fruits. It is possible that in such a deficient population of severely anemic children, a daily recommended amount of the vitamins used was insufficient to enhance treatment response. For example, low DBS retinol , 0.7 mmol/L was prevalent in~70% of children at baseline. We found that DBS retinol increased significantly across all treatment groups and 300 mg/d of vitamin A caused no further increase. This lack of impact of daily vitamin A is unclear, although it is possible that the high dosage of iron may itself have resulted in an improvement in retinol. Iron deficiency has been shown to be associated with impaired vitamin A mobilization from the liver in both animal and human studies (18, 19) . Given the high level of iron deficiency in these severely anemic children, providing iron may have had an overwhelming impact on mobilizing vitamin A stores. Further, subclinical infections were high in this population and vitamin A levels are known to decline in infection and to be nonresponsive to vitamin A supplementation (20) .
Given the low burden of geohelminths, it was not surprising that mebendazole had no detectable effect on response to treatment or in the mean change in Hb concentration, albeit a nonsignificant 26% higher treatment response with mebendazole may perhaps have been due to the low power (,40%). It is likely that mebendazole may have had a systemic effect on reducing subclinical infection, an impact we were unable to assess in our limited DBS analysis of CRP and AGP. High levels of both these acute phase proteins were found in this sample of severely anemic children at baseline.
In this setting, severe dietary insufficiency of iron and a high burden of subclinical infection may be the 2 main factors causing the high rates of severe anemia among children. Widespread and frequent consumption of tea, along with a high phytate wheatbased diet containing low amounts of meat and enhancers of iron absorption such as ascorbic acid-rich foods, may contribute to the problem of severe anemia in this environment.
In conclusion, the current WHO recommendations for treating severe anemia in young children with iron+folic acid treatment revealed a treatment effectiveness of~40%, although higher adherence resulted in a higher treatment response of 50%. In this South Asian setting, where malaria and hookworm prevalence was low, iron+folic acid treatment did just as well alone compared with the addition of anthelminthic and/or multivitamin treatment. Treatment with iron+folic acid in such a setting where anemia is predominantly due to iron deficiency is critical, although achieving high adherence may be challenging in this young age-group. Treatment of infections may also be important for reducing the anemia of infection in these populations.
